What Has Been The Evolution of the Emgality Market in Recent Years?
The emgality market has seen considerable growth due to a variety of factors.
• The market size of emgality has expanded at XX (HCAGR) in the latest years. It is anticipated to rise from $XX million in 2024 to $XX million in 2025, yielding a compound annual growth rate (CAGR) of XX%.
The growth in the historic era has been driven by factors including increased occurrence of migraines, heightened awareness of migraines as a critical health concern, approval of emgality for treating migraines and cluster headaches, a shift in focus towards preventive measures, and assistance from insurance policies.
How Will the Emgality Market?
The emgality market is expected to maintain its strong growth trajectory in upcoming years.
• In the ensuing years, the emgality market is projected to witness a forecasted compound annual growth rate (FCAGR) of XX%.
By 2029, the market is expected to expand to a valuation of $XX million, growing at a compound annual growth rate (CAGR) of XX%.
This growth during the forecasted period could be due to several factors such as penetration into emerging markets, heightened knowledge of migraine remedies, approval for more indications, a rise in health-related spending, and continuous clinical trials. There are several major trends during the projection period which include the rising demand for customized medication, technological progression in drug delivery, improvements in CGRP therapy, integration of digital health, and the application of generative AI in healthcare.
Which Factors Are Boosting Growth In The Emgality Market?
The rising occurrence of migraines is projected to stimulate the expansion of the emgality market in the future. Characterized by severe, pulsating headaches, migraines are a neurological condition often accompanied by symptoms such as nausea, sensitivity to light and sound, and potentially visual or sensory disruptions known as auras. The increasing incidence of migraines is linked to aspects such as escalating stress levels, alterations in lifestyle, environmental catalysts, and enhanced awareness and diagnosis of this condition. Migraines are prevented by Emgality through the blockade of the calcitonin gene-related peptide (CGRP), which in turn lessens the regularity and severity of the attacks. This remedy offers sustained relief, enhancing the quality of life and reducing migraine-related disability among frequent sufferers. As per Migraine Canada in May 2023, a Canada-based group devoted to assisting individuals impacted by migraines, 12% of Canadians (4.5M) and more than 1 billion individuals worldwide are affected by migraines, with women (30% lifetime), compared to males (8%) and children (10%), having a higher prevalence rate. Migraines affect one out of every four households, with 1-2% suffering from chronic migraines. Consequently, the escalating prevalence of migraines is likely to spur the growth of the emgality market.
What Key Areas Define The Segmentation Of The Global Emgality Market?
The emgality market covered in this report is segmented –
1) By Clinical Indication: Migraine Prevention, Cluster Headaches
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Pre-Book The Emgality Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Emgality Market?
A primary trend in the emgality market is leveraging strategic alliances to advance technology amalgamation and to broaden the market penetration. Strategic partnerships are, in essence, relationships between two or more corporations blending their resources, specialization, and endeavors to accomplish shared objectives or targets. For example, in December 2023, Organon & Co., an American health care firm focusing on women's wellness, intensified its collaboration with Eli Lilly, with the objective to broaden the accessibility to the pioneering migraine therapies Emgality and RAYVOW across Europe. This initiative was realized by utilizing Organon's proficiency in central nervous system disorders and formidable commercial capabilities. Emphasizing the significant effects of migraines on women, the collaboration strengthens Organon's product array in the area of women's health. Organon is responsible for the dispersion and promotion of these products, whereas Lilly retains the production and marketing authorization, thereby certifying the effective delivery of these crucial treatments.
Who Are the Key Players In The Emgality Market?
Major companies operating in the emgality market include:
• Eli Lilly and Company
What Is The Most Dominant Region In The Emgality Market?
North America was the largest region in the emgality market in 2024. The regions covered in the emgality market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
